Tirzepatide Side Effects# Well-characterized from Phase 3 (SURPASS, SURMOUNT) trials and post-market surveillance: Gastrointestinal : Nausea (12-33%), diarrhea (12-21%), vomiting (5-12%), constipation (6-11%) Decreased appetite : Common and expected pharmacological effect Injection site reactions : Mild, occurring in 2-5% of patients Pancreatitis : Rare
Quality sleep and weight loss go hand in hand
Henry operates within the recognized cash-pay GLP-1 telehealth model, using licensed clinicians and a 503A compounding pathway with a prescription gate before any medication
For example, exogenous GSH has been recently shown to synergize with meropenem, significantly enhancing the killing of carbapenem-resistant Klebsiella pneumoniae
[5] The EASL suggests using fibrosis tests such as elastography, acoustic radiation force impulse imaging, and serum biomarkers to reduce the number of biopsies
HTR2C polymorphisms and medication-induced weight gain Melanocortin 4 receptor (MC4R) and weight gain References Zepbound Prescribing Information de Mesquita YLL, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao EMH, Carvalho PEP, da Silva CHA, Cardoso R, Moura FA, Rafalskiy VV
